142 related articles for article (PubMed ID: 23050309)
1. Compounded pimobendan for canine chronic degenerative mitral valve disease and pulmonary hypertension.
Helms SR; Fox S; Mixon W; Vail J
Int J Pharm Compd; 2012; 16(1):34-41. PubMed ID: 23050309
[TBL] [Abstract][Full Text] [Related]
2. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
Atkinson KJ; Fine DM; Thombs LA; Gorelick JJ; Durham HE
J Vet Intern Med; 2009; 23(6):1190-6. PubMed ID: 19780931
[TBL] [Abstract][Full Text] [Related]
4. Current use of pimobendan in canine patients with heart disease.
Boswood A
Vet Clin North Am Small Anim Pract; 2010 Jul; 40(4):571-80. PubMed ID: 20610012
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
[TBL] [Abstract][Full Text] [Related]
6. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
Iwanuk N; Nolte I; Wall L; Sehn M; Raue J; Pilgram A; Rumstedt K; Bach JP
BMC Vet Res; 2019 Jul; 15(1):237. PubMed ID: 31288807
[TBL] [Abstract][Full Text] [Related]
7. Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
Iwanuk N; Wall L; Nolte I; Raue J; Rumstedt K; Pilgram A; Sehn M; Rohn K; Bach JP
PLoS One; 2019; 14(10):e0223164. PubMed ID: 31581204
[TBL] [Abstract][Full Text] [Related]
8. Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.
Boswood A; McEwan JD; French A; Little C; Swift S; Smith S; Patteson M
Vet Rec; 2003 Oct; 153(14):439-40. PubMed ID: 14582738
[No Abstract] [Full Text] [Related]
9. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.
Lombard CW; Jöns O; Bussadori CM
J Am Anim Hosp Assoc; 2006; 42(4):249-61. PubMed ID: 16822763
[TBL] [Abstract][Full Text] [Related]
10. The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study.
Klein S; Nolte I; Rumstedt K; Sehn M; Raue JF; Weiner F; Treese JS; Beyerbach M; Bach JP
BMC Vet Res; 2021 Sep; 17(1):310. PubMed ID: 34563187
[TBL] [Abstract][Full Text] [Related]
11. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
Sarcinella F; Neves J; Maddox TW; Hodgkiss-Geere HM; Bode EF; Dukes-McEwan J
Open Vet J; 2020 Jan; 9(4):375-383. PubMed ID: 32042661
[TBL] [Abstract][Full Text] [Related]
12. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
Lake-Bakaar GA; Singh MK; Kass PH; Griffiths LG
J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
McManamey AK; DeFrancesco TC; Meurs KM; Papich MG
J Vet Intern Med; 2023; 37(6):2003-2010. PubMed ID: 37776546
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension.
Morita T; Nakamura K; Osuga T; Kawamoto S; Miki S; Sasaoka K; Takiguchi M
J Vet Cardiol; 2020 Dec; 32():16-27. PubMed ID: 33080489
[TBL] [Abstract][Full Text] [Related]
15. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary hypertension in canine degenerative mitral valve disease.
Kellihan HB; Stepien RL
J Vet Cardiol; 2012 Mar; 14(1):149-64. PubMed ID: 22364721
[TBL] [Abstract][Full Text] [Related]
17. A review of the pharmacology and clinical uses of pimobendan.
Boyle KL; Leech E
J Vet Emerg Crit Care (San Antonio); 2012 Aug; 22(4):398-408. PubMed ID: 22928748
[TBL] [Abstract][Full Text] [Related]
18. Pimobendan in heart failure therapy--a silver bullet?
Gordon SG; Miller MW; Saunders AB
J Am Anim Hosp Assoc; 2006; 42(2):90-3. PubMed ID: 16527909
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
Mizuno M; Yamano S; Chimura S; Hirakawa A; Takusagawa Y; Sawada T; Maetani S; Takahashi A; Mizuno T; Harada K; Shinoda A; Uchida S; Takeuchi J; Mizukoshi T; Endo M; Uechi M
J Vet Med Sci; 2017 Jan; 79(1):29-34. PubMed ID: 27644192
[TBL] [Abstract][Full Text] [Related]
20. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
Apple SM; Menciotti G; Braz-Ruivo L; Crosara S; Häggström J; Borgarelli M
Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
